SCHEMBL24359355

SCHEMBL24359355

OCC1CCCN1C(c1ccccc1)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.46
MEN1 O00255 2/20 0.46
CYP1A2 P05177 1/20 0.44
CYP2D6 P10635 1/20 0.44
HIF1A Q16665 1/20 0.44
L3MBTL3 Q96JM7 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
OPRM1 P35372 5/20 0.40
OPRK1 P41145 5/20 0.40
OPRL1 P41146 5/20 0.40
OPRD1 P41143 4/20 0.40
KDM4E B2RXH2 3/20 0.40
ALDH1A1 P00352 1/20 0.40
CNR1 P21554 1/20 0.39
CNR2 P34972 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3451288 1.00 KMT2A (0.46) KMT2AMEN1CYP1A2CYP2D6HIF1A
SCHEMBL8534618 0.90 OPRM1 (0.46) KMT2AMEN1L3MBTL3L3MBTL1OPRM1
Hydrochloric Acid SCHEMBL11268886 0.88 OPRM1 (0.44) KMT2AMEN1L3MBTL3L3MBTL1OPRM1
SCHEMBL25665529 0.88 SLC6A9 (0.46) KMT2AMEN1CYP1A2CYP2D6HIF1A
SCHEMBL4620185 0.84 KMT2A (0.43) KMT2AMEN1CYP1A2CYP2D6HIF1A
SCHEMBL24359263 0.83 OPRM1 (0.42) KMT2ACYP1A2CYP2D6HIF1AL3MBTL3
SCHEMBL11461803 0.82 SLC18A2 (0.45) CYP1A2CYP2D6HIF1A
SCHEMBL25881974 0.80 MEN1 (0.47) KMT2AMEN1OPRM1OPRK1OPRL1
SCHEMBL17114345 0.80 KDM4E (0.46) KMT2AMEN1CYP1A2CYP2D6HIF1A
SCHEMBL17114344 0.80 KDM4E (0.46) KMT2AMEN1CYP1A2CYP2D6HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230391731-A1 PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF LIANGJIANG MEDICINE CO., LTD. (CN) 2023-12-07 US disclosed
CN-116529252-A Prodrugs for sustained release of therapeutic agents and uses thereof 重庆两江药物研发中心有限公司 2023-08-01 CN disclosed
WO-2022083679-A1 PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF LIANGJIANG MEDICINE CO., LTD. (CN) 2022-04-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230391731-A1 PRODRUGS FOR SUSTAINED RELEASING THERAPEUTIC AGENTS AND USES THEREOF GRPR, SLC2A8, HPGDS KMT2A 4380/4885MEN1 1485/4885CYP1A2 2350/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.